Home › US companies › Solventum

Solventum

SOLV · NYSE · Surgical & Medical Instruments & Apparatus
Insider buys (12 months)
$100K
Insider sales (12 months)
0
8-K reports (12 months)
11
Tracked investors holding
1

At a glance

Solventum reported 2025 revenue of $8.32B, up 0.9% from $8.25B in 2024. Over 3 years since 2022 ($8.13B), that is growth of about 0.8% a year. Operating margin was 26.2%, up from 20.8% in 2022. 2025 was the highest revenue year in this period.

In the last 12 months 1 insider reported 1 open-market purchase ($100K) and 0 sales. The largest was a purchase of $100K by Director Amy Mcbride Wendell on Mar 11, 2026.

Solventum filed 11 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (3), regulation fd disclosure (2) and other events (2). The latest officer or director change was reported on Jul 20, 2026.

1 of the 20 investors tracked here held Solventum at the last quarter end, worth $13.7M combined. It is the largest weight for Bridgewater Associates (0.1% of its portfolio). Added: Bridgewater Associates.

Annual results

2022
Revenue $8.13B
Op. $1.69B
2023
Revenue $8.2B
Op. $1.69B
2024
Revenue $8.25B
Op. $1.04B
2025
Revenue $8.32B
Op. $2.18B
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year2022202320242025
Net income$1.34B$1.35B$479M$1.56B
Diluted EPS$7.78$7.79$2.76$8.88

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Bridgewater AssociatesAdded$13.7M · 0.1% · held 7 quarters

Weight is the share of each investor's portfolio, as of the quarter end.

Current reports (8-K, last 12 months)

Insider open-market trades (last 12 months)

Source: SEC EDGAR. How figures are combined